In both cohorts, CDKN2A genetic alterations were associated with poor response to ICI, either Nivolumab, Ipilimumab or both, and survival in patients with urothelial carcinoma, but no association was observed in the other cancer types, including RCC, which is reminiscent of the conclusion drawn by Baietti et al. [59]. The gene discussed is CDKN2A; the disease is renal cell carcinoma.